Developing novel medicines targeted at the human gut microbiome

Cutting-edge research is highlighting how important the human microbiome is for health. As fundamental science characterizing the complex functions and processes of microbes emerges, many opportunities for microbiome-targeted therapeutics are being presented. Numerous diseases could be prevented and treated through targeted delivery of small molecules, biologics, or probiotics to the human microbiome. Diseases that have been linked with the gut microbiome include cardiovascular disease, diabetes mellitus, colon cancer, Parkinson’s disease, autism spectrum disorder, and depression. 

This PhD project will focus on developing new medicines targeted at the gut microbiome. The successful applicant will receive training in all relevant areas of the project, including the use of machine learning to streamline and enhance the impact of laboratory results. Upon starting, the PhD candidate will join a renowned research group, supervised by Professor Abdul W. Basit, with multiple decades of academic and commercial experience in microbiome medicine. The project will be based at University College London (UCL), a top 10 University in the 2024 QS World Rankings, within the vibrant and welcoming School of Pharmacy. During their project, the PhD researcher will have access to gold-standard facilities and resources, with strong mentorship, support, and frequent career development opportunities.  

Applications 

Applicants should be enthusiastic about research and be keen to work on the development of novel microbiome-targeted medicines. The ideal candidate should have (or expect to achieve) a bachelor’s degree or relevant master’s qualification in Pharmacy, Biochemistry, Engineering or a related discipline. Prior lab experience and Data Science knowledge will be valued. A good level of spoken and written English is essential. Applications are welcomed from both UK and overseas candidates. To apply, please send a CV and cover letter to a.basit@ucl.ac.uk.